Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: Assessment in an unselected non-referral based patient population

Heart

Volumn 79, Issue 4, 1998, Pages 331-336

  Cecchi, F ^a,c   Olivotto, I ^a   Montereggi, A ^a   Squillatini, G ^a   Dolara, A ^a   Maron, B J ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^c NONE   (Italy)

Author keywords

Amiodarone; Hypertrophic cardiomyopathy; Ventricular tachycardia

Indexed keywords

AMIODARONE;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; DIAGNOSTIC VALUE; FEMALE; HEART VENTRICLE TACHYCARDIA; HIGH RISK POPULATION; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; SUDDEN DEATH;

EID: 0031978633     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.79.4.331     Document Type: Article

References (42)

1. Maron BJ, Bonow RO, Cannon RO, et al. Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology, and therapy. N Engl J Med 1987;316:780-9, 844-52.
2. McKenna W, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47:532-8.
3. Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. Circulation 1968;37:759-88.
4. Shah PM, Adelman AG, Wigle ED, et al. The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. Circ Res 1973;34/35(suppl 2):II-179-95.
5. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy: the importance of the site and extent of hypertrophy - a review. Progr Cardiovasc Dis 1985;28:1-83.
6. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: profile of 78 patients. Circulation 1982;65:1388-94.
7. Swan DA, Bell B, Oakley C, et al. Analysis of symptomatic course and prognosis and treatment of hypertrophic obstructive cardiomyopathy. Br Heart J 1971;33:671-85.
8. Hardarson T, De La Calzada CS, Curiel R, et al. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet 1973;ii:1462-7.
9. Loogen F, Kuhn H, Gietzen F, et al. Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non-obstructive cardiomyopathy. Eur Heart J 1983;4(suppl F):145-53.
10. Hecht GM, Panza JA, Maron BJ. Clinical course of middle-aged asymptomatic patients with hypertrophic cardiomyopathy. Am J Cardiol 1992;69:935-40.
11. McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child 1984; 59:971-5.
12. Fiddler GI, Tajik AJ, Weidman WH, et al. Idiopathic hypertrophic subaortic stenosis in the young. Am J Cardiol 1978; 42:793-9.
13. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989;13: 1283-8.
14. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy: assessment of patients at high risk. Circulation 1989;80:1489-92.
15. McKenna WJ, Counihan PJ, Chikamori T. Sudden death in hypertrophic cardiomyopathy: identification and management of high risk patients. In: Baroldi G, Camerini F, Goodwin JF, eds. Advances in cardiomyopathies. Berlin: Springer-Verlag, 1990:72-80.
16. Watkins H, Rosenzweig A, Hwang D-S, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108-14.
17. Maron BJ, Cecchi F, McKenna WJ. Risk factors and current status of risk stratification profiles for sudden cardiac death in patients with hypertrophic cardiomyopathy. Br Heart J 1994;72(suppl):S14-18.
18. Maron BJ, Savage DD, Wolfson JK, et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981;48:252-7.
19. Savage DD, Seides SF, Maron BJ, et al. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation. 1979;59:866-75.
20. McKenna WJ, England D, Doi YL, et al. Arrhythmia in hypertrophic cardiomyopathy: I. Influence on prognosis. Br Heart J 1981;46:168-72.
21. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985;53:412-16.
22. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994;90: 2743-7.
23. Cecchi F, Olivotto I, Montereggi A, et al. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected population. J Am Coll Cardiol 1995;26:1529-36.
24. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993;72:970-2.
25. Shapiro LM, Zezulka A. Hypertrophic cardiomyopathy: a common disease with a good prognosis - five year experience of a district general hospital. Br Heart J 1983;50:530-3.
26. Kofflard MJ, Waldstein DJ, Vos J, et al. Prognosis in hypertrophic cardiomyopathy: long-term follow-up in a large, unselected outpatient population. Am J Cardiol 1993;72: 939-43.
27. Spirito P, Chiarella F, Carratino L, et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989;320:749-55.
28. Fananapazir L, Leon MB, Bonow RO, et al. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991;67:169-74.
29. McKenna WJ, Harris L, Perez G, et al. Arrhythmia in hypertrophic cardiomyopathy: II. Comparison of amiodarone and verapamil in treatment. Br Heart J 1981;46:173-8.
30. McKenna WJ, Harris L, Rowland E, et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol 1984;54:802-10.
31. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide angle, two-dimensional echocardiographic study of 125 patients. Am J Cardiol 1981;48:418-28.
32. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol 1983;2:437-44.
33. Panza JA, Petrone RK, Fananapazir L, et al. Utility of continuous wave Doppler in noninvasive assessment of the left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 19:91-9.
34. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
35. Spirito P, Maron BJ, Bonow RO, et al. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in patients with hypertrophic cardiomyopathy. Am J Cardiol 1987;60:123-9.
36. Frenneaux MP, Counihan PJ, Porter A, et al. Effects of amiodarone on erect and supine exercise haemodynamics and exercise capacity in patients with hypertrophic cardiomyopathy. Eur Heart J 1992;13:687-96.
37. Sugrue DD, Dickie S, Myers MJ, et al. Effect of amiodarone on left ventricular ejection and filling in hypertrophic cardiomyopathy as assessed by radionuclide angiography. Am J Cardiol 1984;54:1054-8.
38. Debbas NMG, du Cailar C, Bexton RS, et al. The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J 1984;51:316-20.
39. Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
40. Friedman PL, Stevenson WG. Unsustained ventricular tachycardia - to treat or not to treat? N Engl J Med 1996;335:1984-5.
41. Singh BN. Amiodarone: historical development and pharmacological profile. Am Heart J 1983;106:788-97.
42. Greene HL. The CASCADE study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle: CASCADE Investigators. Am J Cardiol 1993;13: 442-9.